Elmind Capital LP Acquires Shares of 801,300 KalVista Pharmaceuticals, Inc. $KALV

Elmind Capital LP acquired a new stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) during the 4th quarter, HoldingsChannel.com reports. The institutional investor acquired 801,300 shares of the specialty pharmaceutical company’s stock, valued at approximately $12,941,000. KalVista Pharmaceuticals accounts for 3.8% of Elmind Capital LP’s holdings, making the stock its 11th biggest position.

Several other institutional investors also recently bought and sold shares of KALV. Tudor Investment Corp ET AL acquired a new stake in KalVista Pharmaceuticals in the third quarter valued at approximately $24,360,000. Parkman Healthcare Partners LLC grew its holdings in KalVista Pharmaceuticals by 155.5% in the third quarter. Parkman Healthcare Partners LLC now owns 1,735,003 shares of the specialty pharmaceutical company’s stock valued at $21,132,000 after purchasing an additional 1,055,940 shares during the period. Ameriprise Financial Inc. grew its holdings in KalVista Pharmaceuticals by 2,258.6% in the second quarter. Ameriprise Financial Inc. now owns 945,125 shares of the specialty pharmaceutical company’s stock valued at $10,685,000 after purchasing an additional 905,053 shares during the period. Armistice Capital LLC acquired a new stake in KalVista Pharmaceuticals in the fourth quarter valued at approximately $12,920,000. Finally, Freestone Grove Partners LP acquired a new stake in KalVista Pharmaceuticals in the third quarter valued at approximately $8,580,000.

Wall Street Analysts Forecast Growth

Several analysts have commented on KALV shares. Weiss Ratings reissued a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Tuesday, April 21st. Citizens Jmp downgraded KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 29th. JonesTrading downgraded KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, April 30th. Needham & Company LLC downgraded KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, April 30th. Finally, Wall Street Zen upgraded KalVista Pharmaceuticals to a “hold” rating in a research report on Saturday, June 13th. Three analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $30.60.

KalVista Pharmaceuticals Stock Performance

NASDAQ KALV opened at $27.00 on Thursday. The company has a market cap of $1.44 billion, a PE ratio of -7.80 and a beta of -0.12. The stock’s 50 day simple moving average is $24.58 and its 200-day simple moving average is $19.11. KalVista Pharmaceuticals, Inc. has a 1-year low of $9.83 and a 1-year high of $27.00. The company has a debt-to-equity ratio of 8.18, a current ratio of 5.17 and a quick ratio of 5.10.

KalVista Pharmaceuticals (NASDAQ:KALV) last released its earnings results on Thursday, May 14th. The specialty pharmaceutical company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.05). The firm had revenue of $40.86 million during the quarter, compared to analyst estimates of $39.03 million. As a group, equities research analysts anticipate that KalVista Pharmaceuticals, Inc. will post -1.19 EPS for the current fiscal year.

Insider Activity at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, insider Paul K. Audhya sold 2,686 shares of the business’s stock in a transaction on Friday, April 17th. The stock was sold at an average price of $20.22, for a total transaction of $54,310.92. Following the transaction, the insider owned 142,547 shares of the company’s stock, valued at approximately $2,882,300.34. The trade was a 1.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Brian Piekos sold 1,862 shares of the business’s stock in a transaction on Friday, April 17th. The stock was sold at an average price of $20.22, for a total value of $37,649.64. Following the transaction, the chief financial officer directly owned 18,150 shares in the company, valued at $366,993. This trade represents a 9.30% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 254,602 shares of company stock valued at $4,656,670 in the last three months. Company insiders own 4.30% of the company’s stock.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.